Nichole Tucker

Managing Editor

Nichole Tucker is the Managing Editor of Blood Cancers Today. Tucker has spent over 11 years curating storytelling pieces in healthcare, public health, and life sciences. She holds a Master’s degree in International Media from University College Dublin and a bachelor’s degree in Mass Communications from Virginia State University.

Articles by Nichole Tucker

Ruben A. Mesa, MDMyeloproliferative Neoplasms | June 6, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
View More
Nichole TuckerMeeting News | June 1, 2025
Cilta-cel improves PFS and OS in len-refractory MM across subgroups, including high-risk cytogenetics, per CARTITUDE-4.
Nichole TuckerMyelodysplastic Syndromes | June 10, 2025
IME shows strong efficacy in LR-MDS, offering transfusion independence in heavily pretreated, ESA-ineligible patients.
Nichole TuckerAggressive B-Cell Lymphoma | June 1, 2025
EPCOR shows durable remission and survival at 2 years in R/R LBCL, with promising safety from fixed-duration treatment.
Nichole TuckerTransplantation & Cellular Therapy | May 29, 2025
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Nichole TuckerAcute Myeloid Leukemia | May 27, 2025
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Nichole TuckerMyelodysplastic Syndromes | May 13, 2025
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
Nichole TuckerChronic Lymphocytic Leukemia | May 14, 2025
CLL treatment is evolving. Dr. Ryan Jacobs shares why decisions now weigh indefinite therapy vs. time-defined options.
Nichole TuckerAcute Lymphoblastic Leukemia | May 6, 2025
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
Nichole TuckerMeeting News | May 1, 2025
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
Nichole TuckerT-Cell Lymphoma | April 11, 2025
Linperlisib will be investigated in a global registration study versus physician’s choice of standard treatment for R/R ...
Nichole TuckerAggressive B-Cell Lymphoma | April 15, 2025
Pallawi Torka, MD, discusses current guidelines and evidence-based strategies for managing DLBCL in older adults.
Nichole TuckerAggressive B-Cell Lymphoma | April 9, 2025
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
Nichole TuckerAcute Lymphoblastic Leukemia | April 15, 2025
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
Nichole TuckerAggressive B-Cell Lymphoma | April 1, 2025
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Nichole TuckerMyelofibrosis | March 25, 2025
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
Nichole TuckerAcute Myeloid Leukemia | April 2, 2025
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
Nichole TuckerMyeloma | March 10, 2025
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
Nichole TuckerMeeting News | March 7, 2025
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
Nichole TuckerMeeting News | February 21, 2025
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.